AI Medical Service Inc.

AI Medical Service Inc. is a company in Tokyo, Japan, whose business is the development of endoscopic AI (artificial intelligence) to support diagnostic imaging and related activities. It was founded on September 1, 2017, and its mission is to save lives all over the world and eliminate overlooked cancer through endoscopic AI. The company states that GI cancers (from esophageal cancer to rectal cancer) are the largest cause of cancer mortality worldwide, accounting for approximately 30% of all cancer deaths, and that about 20% of cancers are overlooked due to the limitations of human observation; AI Medical Service was founded to take on these issues with AI. Its executive leadership includes Tomohiro Tada and Yasushi Takigawa. As of September 2025 it had 100 employees (including directors and interns) and capital of 13.8 billion yen (including reserves). It holds ISO27001, ISO27701 and ISO13485 certifications, and has a Singapore branch in addition to its Tokyo headquarters.

AI Medical Service Inc. was founded on September 1, 2017. In January 2018 it developed the world's first AI for gastric cancer detection using still images, and in August 2018 it raised funds during a series A round. In January 2019 it developed the world's first AI for esophageal detection using still images, and in March 2019 the world's first AI for esophageal detection using videos. In October 2019 it raised funds during a series B round, and in November 2019 it received designated breakthrough device designation from the U.S. Food and Drug Administration (FDA) for its endoscopic system. In February 2020 it was awarded "EY Innovative Startup 2020"; in April 2020 it demonstrated that AI for gastric cancer detection significantly outperforms endoscopists in terms of sensitivity and was awarded the "Fifth JEITA Venture Award"; in August 2020 it relocated its headquarters to Hareza Tower; and in October 2020 it was awarded the Grand Prix in the Co-Creation PARK section on "CEATEC AWARD 2020". In June 2021 it was awarded as Technology Pioneer by the World Economic Forum. In November 2022 it acquired ISO27001 and ISO27701 certifications, and in December 2022 ISO13485. In November 2022 CEO Dr. Tada spoke at the Stanford Gastric Cancer Summit. In August 2024 it was selected for the "Forbes Asia 100 To Watch 2024". In May 2025 it announced the release of "Article Collection: Artificial Intelligence in Gastroenterology," co-edited by CEO Dr. Tomohiro Tada; in July 2025 it won the METI Minister's Award at GHeC and obtained regulatory approval from Thailand's FDA for its gastric AI-based endoscopic diagnosis support system; and in October 2025 it was recognized as a winner at CHISEL Healthcare InnoMatch 2025 in Singapore. In May 2026 it received manufacturing and marketing approval in Japan for Endoscopic Image Diagnosis Support Software "gastroAI model-G3".

Redefine GI cancer diagnostics with AI; Japanese innovation revolutionizing medicine worldwide.

• gastroAI model-G3

  Endoscopic Image Diagnosis Support Software that received manufacturing and marketing approval in Japan.

• Gastric AI-based endoscopic diagnosis support system

  Obtained regulatory approval from Thailand's FDA.

1. 1AI Medical Service Corporation｜Saving Patients Around the World | AI Medical Service Inc.en.ai-ms.com
2. 2About us | AI Medical Service Inc.en.ai-ms.com
3. 3Company Information | AI Medical Service Inc.en.ai-ms.com
4. 4Corporate | News | AI Medical Service Inc.en.ai-ms.com
5. 5AI Medical Service Inc. (Japan)wikidata.org